Loading…
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 This bill addresses Medicare coverage for and access to treatment for chronic kidney disease. Specifically, the bill modifies provisions related to coverage by (1) allowing certain Medicare beneficiaries who have End Stage Renal Disease to enroll in Medicare supplemental policies, and (2) establishing new Medicare payment structures for renal dialysis services. Among other changes, the bill (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services. In addition, the bill requires information sharing between hospitals and renal dialysis centers in some circumstances as well as federal studies on issues related to kidney disease, including the use of palliative care and ways to increase transplantation rates. The Department of Health and Human Services may also award National Health Services Corps scholarships and loan repayment to nephrology health professionals.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (11)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Medicare/Medicaid
H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Health Issues
H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912/S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,100,000 · Firm income: Not reported
2020 · fourth_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R. 6800, The Heroes Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020; Extension of the Medicare Sequester
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment, including the ESRD Prospective Payment System Regulation and S. 1676 /H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Medicare/Medicaid
S.1676, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ETC Program. Issues related to H.R.748/S.3548, CARES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; NOTA proposed and final rule; OPO proposed and final rule; CARES Act; HHS COVID-19 Interim Final Rules; H.R.133 - Consolidated Appropriations Act, 2021; vaccine prioritization issues
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · fourth_quarter · Medicare/Medicaid
ESRD Prospective Payment System CY 2021 and Quality Incentive Program PY 2023-24 Proposed Rule; Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies; H.R.133 - Consolidated Appropriations Act, 2021; vaccine prioritization issues
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · fourth_quarter · Health Issues
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act H.R. 133, Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. H.R. 2710 - Patient Access to ESRD New Innovative Devices Act. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 133, Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19 H.R. 5534/S. 3353 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133 Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,080,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Medicare/Medicaid
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19 H.R. 5534/S. 3353 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133 Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,080,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. H.R. 2710 - Patient Access to ESRD New Innovative Devices Act. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136 H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136 H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R. 6800, The Heroes Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment, including the ESRD Prospective Payment System Regulation and S. 1676 /H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Medicare/Medicaid
Dialysis PATIENTS Demonstration Act, all provisions (no bill number this Congress) CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act H.R. 1224, The Living Donor Protection Act, all provisions Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act Worked with HHS, CMS and FEMA on emergency response related to COVID-19
Client expense: $1,540,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · first_quarter · Health Issues
Dialysis PATIENTS Demonstration Act, all provisions (no bill number this Congress) CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act H.R. 1224, The Living Donor Protection Act, all provisions Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act Worked with HHS, CMS and FEMA on emergency response related to COVID-19
Client expense: $1,540,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · second_quarter · Health Issues
Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · second_quarter · Medicare/Medicaid
Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Medicare/Medicaid
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $860,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Health Issues
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $860,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Health Issues
Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; NOTA proposed and final rule; OPO proposed and final rule; CARES Act; HHS COVID-19 Interim Final Rules
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · third_quarter · Medicare/Medicaid
ESRD Prospective Payment System CY 2021 and Quality Incentive Program PY 2023-24 Proposed Rule; Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · third_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
S.1676, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ETC Program. Issues related to H.R.748/S.3548, CARES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R, 6800, HEROES Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronovirus Aid, Relief, and Economic Security (CARES) Act
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Medicare/Medicaid
Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · second_quarter · Health Issues
Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; CARES Act; HHS COVID-19 Interim Final Rules
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · second_quarter · Medicare/Medicaid
Better Kidney Care Act (Draft Bill) CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · second_quarter · Health Issues
Better Kidney Care Act (Draft Bill) CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · second_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
S.1676, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ETC Program. Issues related to H.R.748/S.3548, CARES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136 H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Medicare/Medicaid
Issues related to End Stage Renal Disease; Acute Kidney Injury; Dialysis. S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2019. H.R. 2710 - Patient Access to ESRD New Innovative Devices Act. ESRD Treatment Choices Model. Issues related to Medicare Advantage; Better Kidney Care Act. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136 H.R. 266, Paycheck Protection Program and Health Care Enhancement Act H.R. 6800, HEROES Act H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; HRSA organ compensation proposed rule, CARES Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · first_quarter · Medicare/Medicaid
Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
2020 · first_quarter · Medicare/Medicaid
Medicare Part B coverage and reimbursement issues Issues related to International Pricing Index (IPI), no specific bill Coding and reimbursement for biologics/biosimilars Issues related to Part D redesign, no specific bill Issues related to Part D rebate reform, no specific bill Medicare Part D access issues for plan year 2020, no specific bill S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues H.R. 2296/S 1391 FAIR Drug Pricing Act S. 1416 Affordable Prescriptions for Patients Act Issues related to Direct to Consumer Advertisement Issues related to Biosimilars, no specific bill Prescription drug value issues, no specific bill S. 1664, Prescription Drug Price Reporting Act H.R. 3 - Lower Prescription Drug Costs Now Act H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019 Issues related to the Center for Medicare & Medicaid Innovation S. 2543 Prescription Drug Pricing Reduction Act Section 210- Applying Medicaid Drug Rebate Requirement to Drugs Provided as Part of Outpatient Hospital Services H.R. 19/S. 3129 Lower Costs, More Cures Act 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and cost-sharing assistance. HR 748 Coronavirus Aid, Relief, and Economic Security (CARES) Act and access to Part B medicines at home Issues related to the 340B program, no specific bill
Client expense: $2,700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
2020 · first_quarter · Medical/Disease Research/Clinical Labs
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R> 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 Administrative action to provide relief for health care providers during the COVID-19 crisis.
Client expense: $450,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE